Literature DB >> 20630490

Dysregulation of developmental pathways in bone metastasis.

Nilay Sethi1, Yibin Kang.   

Abstract

It is well-known that pathways normally functioning during embryonic development are dysregulated in cancer. Experimental and clinical studies have established strong connections between aberrant developmental pathways and transformation, as well as other early stage events of cancer progression. There is now emerging evidence that also indicates the contribution of developmental pathways to the pathogenesis of distant metastasis, including bone metastasis. In particular, the Wnt, BMP, and Hedgehog signaling pathways have all been implicated in the development of bone metastasis. These developmental pathways participate in the regulation of cell-autonomous functions in tumor cells as well as tumor-stromal interactions in the bone microenvironment, eventually promoting the formation of osteolytic or osteoblastic bone metastasis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20630490     DOI: 10.1016/j.bone.2010.07.005

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  23 in total

1.  Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.

Authors:  Amber Jin Giles; Caitlin Marie Reid; Justin DeWayne Evans; Meera Murgai; Yorleny Vicioso; Steven Lorenz Highfill; Miki Kasai; Linda Vahdat; Crystal Lee Mackall; David Lyden; Leonard Wexler; Rosandra Natasha Kaplan
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

2.  Curcumin, but not curcumin-glucuronide, inhibits Smad signaling in TGFβ-dependent bone metastatic breast cancer cells and is enriched in bone compared to other tissues.

Authors:  Andrew G Kunihiro; Julia A Brickey; Jennifer B Frye; Paula B Luis; Claus Schneider; Janet L Funk
Journal:  J Nutr Biochem       Date:  2018-10-11       Impact factor: 6.048

3.  Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.

Authors:  Hanna Taipaleenmäki; Gillian Browne; Jacqueline Akech; Jozef Zustin; Andre J van Wijnen; Janet L Stein; Eric Hesse; Gary S Stein; Jane B Lian
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

Review 4.  Unravelling the complexity of metastasis - molecular understanding and targeted therapies.

Authors:  Nilay Sethi; Yibin Kang
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 5.  MicroRNAs as regulators of bone homeostasis and bone metastasis.

Authors:  Brian Ell; Yibin Kang
Journal:  Bonekey Rep       Date:  2014-07-02

Review 6.  BMPs and their clinical potentials.

Authors:  Meejung Kim; Senyon Choe
Journal:  BMB Rep       Date:  2011-10       Impact factor: 4.778

7.  miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells.

Authors:  Mohammad Q Hassan; Yukiko Maeda; Hanna Taipaleenmaki; Weibing Zhang; Mohammad Jafferji; Jonathan A R Gordon; Zhaoyong Li; Carlo M Croce; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

Review 8.  Reader's digest of the pathophysiology of bone metastases.

Authors:  Reinhard Gruber
Journal:  Wien Med Wochenschr       Date:  2012-07-14

Review 9.  Notch signalling in cancer progression and bone metastasis.

Authors:  N Sethi; Y Kang
Journal:  Br J Cancer       Date:  2011-11-10       Impact factor: 7.640

10.  Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2.

Authors:  Rumela Chakrabarti; Julie Hwang; Mario Andres Blanco; Yong Wei; Martin Lukačišin; Rose-Anne Romano; Kirsten Smalley; Song Liu; Qifeng Yang; Toni Ibrahim; Laura Mercatali; Dino Amadori; Bruce G Haffty; Satrajit Sinha; Yibin Kang
Journal:  Nat Cell Biol       Date:  2012-10-21       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.